Skip to main content

Advertisement

Table 7 Incidences of adjudication-confirmed cases of pancreatitis and prespecified hypersensitivity adverse events in the APaT population; Treatment Period + all follow-up days

From: A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

Patients, n (%) Omarigliptin N = 2092 Placebo N = 2100
With pancreatitis
 Acute 6 (0.3) 3 (0.1)
 Chronic 0 (0.0) 1 (<0.1)
With hypersensitivity
 Angioedema 4 (0.2) 1a (0.1)
 Asthma–bronchospasm 2 (0.1) 2 (0.1)
 Anaphylaxis 0 (0.0) 1 (<0.1)
  1. aOne patient in the placebo group was reported to have experienced two cases of angioedema